Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center

Cancer

Volumn 112, Issue 10, 2008, Pages 2211-2220

  Storey, Dawn J ^a   Rush, Robert ^b   Stewart, Moira ^a   Rye, Tzyvia ^a   Al Nafussi, Awatif ^c   Williams, Alistair R ^c   Smyth, John F ^a   Gabra, Hani ^d  

^a Edinburgh Cancer Centre   (United Kingdom)

^b QUEEN MARGARET UNIVERSITY   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d Ovarian Cancer Action (HHMT) Research Unit   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Endometrioid; Ovary; Platinum; Predictors; Survival

Indexed keywords

PLATINUM;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVARY ADENOCARCINOMA; OVARY CANCER; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 43049105741     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23438     Document Type: Article

References (32)

1. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
2. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044.
3. Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004;100:2148-2153.
4. Long ME, Taylor HC Jr. Endometrioid carcinoma of the ovary. Am J Obstet Gynecol. 1964;90:936-950.
5. Brescia RJ, Dubin N, Demopoulos RJ. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. Int J Gynecol Pathol. 1989;8:132-128.
6. Grosso G, Raspagliesi F, Baiocchi G, Di Re E, Colavita M, Cobellis L. Endometrioid carcinoma of the ovary: a retrospective analysis of 106 cases. Tumori. 1998;84:552-557.
7. Kline RC, Wharton JT, Atkinson EN, Burke TW, Gershenson DM, Edwards CL. Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol. 1990;39:337-346.
8. Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004;94:456-462.
9. Tidy I, Mason WP. Endometrioid carcinoma of the ovary: a retrospective study. Br J Obstet Gynaecol. 1988;95:1165-1169.
10. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously detected endometrial and ovarian carcinomas - a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol. 2001;83:355-362.
11. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol. 1971;37:1-9.
12. Czernobilsky B, Silverman BB, Mikuta JJ. Endometrioid carcinoma of the ovary. A clinicopathologic study of 75 cases. Cancer. 1970;26:1141-1152.
13. Dembo AJ, Bush RS. Current concepts in cancer: ovary-treatment of stages III and IV. Choice of postoperative therapy based on prognostic factors. Int J Radiat Oncol Biol Phys. 1982;8:893-897.
14. Einhorn N, Nilsson B, Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer. 1985;55:2019-2025.
15. Malkasian GD Jr, Melton LJ 3rd, O'Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol. 1984;149:274-284.
16. Sorbe B, Frankendal B, Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol. 1982;59:576-582.
17. Tornos C, Silva EG, Khorana SM, Burke TW. High-stage endometrioid carcinoma of the ovary. Prognostic significance of pure versus mixed histologic types. Am J Surg Pathol. 1994;18:687-693.
18. Shevehuk MM, Winkler-Monsanto B, Fenoglio CM, Richart RM. Clear cell carcinoma of the ovary: a clinicopathologic study with review of the literature. Cancer. 1981;47:1344-135.
19. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7:361-364.
20. Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol. 2000;18:1733-1739.
21. Bjorkholm E, Pettersson F, Einhorn N, Krebs I, Nilsson B, Tjernberg B. Long-term follow-up and prognostic factors in ovarian carcinoma. The radiumhemmet series 1958 to 1973. Acta Radiol Oncol. 1982;21:413-419.
22. Zwart J, Geisler JP, Geisler HE. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma. Eur J Gynaecol Oncol. 1998;19:225-228.
23. Garzetti GG, Ciavattini A, Goteri G, et al. Endometrioid carcinoma of the ovary. Retrospective study. Eur J Gynaecol Oncol. 1993;14:51-55.
24. Voest HL, van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log |relative risk|) as main objectives. Eur J Cancer Clin Oncol. 1989;25:711-720. Comment in: Eur J Cancer Clin Oncol. 1989;25:1901.
25. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/ MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998;58:2095-2097.
26. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052-7056.
27. Saito M, Okamoto A, Kohno T, et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer. 2000;85:160-165.
28. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678-7681.
29. Catasus L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol. 2004;35:1360-1368.
30. Lassus H, Leminen A, Lundin I, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003;91:504-512.
31. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clinical Cancer Res. 2001;7:2984-2997.
32. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007;11:321-333.